Advanced Enzyme Technologies Q1 FY27: Modest revenue growth, softer margins, and a clear focus on capital allocation

Advanced Enzyme Technologies Limited opened FY27 with a steady but muted quarter. Consolidated revenue from operations in Q1 FY27 stood at INR 1,898 million, up 2% year-on-year from INR 1,859 million. Profitability, however, softened. EBITDA declined 10% YoY to INR 510 million, while PAT fell 5% YoY to INR 386 million. EBITDA margin and PAT margin for the quarter were 27% and 20% respectively.

Management framed the quarter as a soft start in a volatile macro environment. The commentary pointed to elevated power and fuel costs, a temporary shift in sales mix, and lower realizations. A key operational factor was an additional sales reversal of around INR 100 million due to revenue recognition rules for goods in transit. Management stated that this reversal had already been recorded as of the call date, and that the revenue pipeline remains intact.

Segment mix: Human Nutrition weak, Bio-processing and Specialized Manufacturing strong

The quarter’s segment performance showed a clear divergence. Human Nutrition, the largest contributor at around 60% of sales, declined. Segment revenue fell 7% YoY to INR 1,139 million, with management attributing the decline primarily to lower sales in the Pharma API business. Animal Nutrition revenue was INR 252 million, down 3% YoY, contributing around 13% of total revenue.

Growth came from the industrial side. Industrial Bio-processing delivered 30% YoY growth to INR 306 million and contributed around 16% of revenue. Within this segment, the food business grew strongly to INR 263 million, while non-food stood at INR 43 million. Specialized Manufacturing continued its momentum with revenue of INR 200 million, up 41% YoY, contributing 11% of sales.

Geography: Europe and Asia grew, India and Americas softened

Geographically, the quarter reflected a mixed demand environment. India remained the largest market at 49% share, with revenue of INR 937 million, down 4% YoY. The Americas represented 29% of sales at INR 546 million, down 3% YoY.

The strongest growth came from Europe and Asia (excluding India). Europe grew 44% YoY to INR 132 million, while Asia grew 37% YoY to INR 242 million. Rest of the World remained small at INR 40 million, down 15% YoY.

The management discussion also highlighted the variability that can arise quarter to quarter due to order timing, export shipment delivery and revenue recognition for goods in transit. This was specifically relevant in Q1 FY27 because of the higher-than-usual sales reversal.

Margin commentary: energy costs and mix headwinds, normalization expected

Operating margins moderated in Q1 FY27, with management attributing the decline to three drivers: lower top-line realization, elevated energy costs, and a temporary shift in sales mix. The company reiterated its focus on cost optimization and operational efficiencies.

On the call, management stated it expects EBITDA margins to return to around 30% for the rest of the year. This is an important marker because the company’s longer-term profile has been built around stable profitability and low leverage.

Working capital commentary was limited, but management indicated a typical cycle of about 125 to 138 days. It also shared quarter-end working capital components: inventory of about INR 190 crore, receivables of about INR 131 crore, and payables of about INR 41 crore.

Capital allocation and structure: buyback, JC Biotech acquisition, and capex

Beyond operating performance, the quarter carried meaningful corporate actions. The board approved an open market buyback of up to INR 697 million at a maximum price of INR 500 per share. At the maximum size and price, the indicative maximum buyback quantity is 1,394,000 shares, about 1.24% of the existing paid-up capital.

The company also approved acquisition of the remaining 4.28% stake in JC Biotech Private Limited for INR 79.79 million (INR 90 per share), taking the holding to 100% and making it a wholly owned subsidiary. The stated rationale was to optimize synergies across business operations at the consolidated level. The indicative completion timeline mentioned in the announcement was September 30, 2026.

In parallel, the board approved additional funding up to INR 20 million in Advanced Nutrazyme Private Limited, its wholly owned subsidiary intended for sales and distribution of the company’s nutrition and wellness range. The announcement indicated an indicative timeline up to December 31, 2027.

Management also discussed a capex program of about INR 123 crore as referenced in the AGM. It stated that around INR 20 crore is regular capex, around INR 50 crore relates to R&D capex work-in-progress expected to become functional in the next quarter or so, and the balance is for growth. Management noted fermentation utilization at around 70-75% and indicated that a capacity expansion decision could be taken in the next quarter.

What to track from here

Q1 FY27 highlighted two opposing forces. On one hand, the company demonstrated resilience through diversified segments, with Bio-processing and Specialized Manufacturing delivering strong growth. On the other, the core Human Nutrition segment declined and margins softened, driven by energy costs and mix.

Management’s near-term confidence rests on three levers: normalization of sales reversals as shipments get delivered, margin recovery toward 30% EBITDA, and stronger momentum in the second half for focus areas such as biocatalysis. Investors will likely track whether Human Nutrition returns to growth, whether U.S. performance improves as branding strategy progresses, and whether the capex program translates into sustained volume and product momentum.

The corporate actions add a second layer to the story. The buyback signals shareholder-friendly capital allocation, while JC Biotech moving to wholly owned status indicates tighter control over a meaningful subsidiary. If the company can translate these structural steps into more consistent execution, FY27 could show a stronger profile than the first quarter suggests.